• Explore /
  • Poster
  • / Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).

Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).

Abstract Poster

Authors

null

Joaquim Bellmunt

Dana-Farber Cancer Institute, Boston, MA

Joaquim Bellmunt , Ronald De Wit , David J. Vaughn , Yves Fradet , Jae-Lyun Lee , Lawrence Fong , Nicholas J. Vogelzang , Miguel A. Climent , Daniel Peter Petrylak , Toni K. Choueiri , Andrea Necchi , Winald Gerritsen , Howard Gurney , David I. Quinn , Stephane Culine , Cora N. Sternberg , Kijoeng Nam , Tara L. Frenkl , Rodolfo F. Perini , Dean F. Bajorin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT02256436

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 410)

DOI

10.1200/JCO.2018.36.6_suppl.410

Abstract #

410

Poster Bd #

A7

Abstract Disclosures

Similar Posters

First Author: Yves Fradet

First Author: Joaquim Bellmunt

First Author: Joaquim Bellmunt

First Author: Brian M. Slomovitz